{"filings":[{"id":1278796,"accession_number":"0001193125-26-282994","cik":1671858,"company_name":"ARS Pharmaceuticals, Inc.","ticker":"SPRY","form_type":"8-K","filed_at":"2026-06-25T21:01:07+00:00","items":["5.07"],"status":"ready","headline":"ARS Pharma stockholders elect Class III directors, ratify EY, approve say-on-pay","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Saqib Islam, Phillip Schneider, Laura Shawver elected as Class III directors; Schneider received 38.5M for vs 27.5M withheld.","Ernst & Young ratified as auditor for FY2026 with 79.5M for, 102k against.","Advisory vote on NEO compensation approved with 57.3M for, 8.1M against, 622k abstain.","Advisory vote selects 1-year frequency for future say-on-pay votes (52.1M votes) until 2032 meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":874861795.2258824,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":451879,"accession_number":"0001193125-26-225055","cik":1671858,"company_name":"ARS Pharmaceuticals, Inc.","ticker":"SPRY","form_type":"8-K","filed_at":"2026-05-15T10:02:44+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"ARS Pharma reports Q1 revenue $22.7M, neffy net product revenue $17.5M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $60.6M ($0.61/share); cash $201M; expects to fund to cash-flow break-even.","CVS Caremark formulary proposal in final stages; target July 1, 2026; gross-to-net target ~50%.","Sales force expanded to 148 reps; SG&A $72.2M includes DTC marketing investment.","Health Canada approved neffy on April 15; EU 1 mg dose approved for children 4+ years.","Phase 2b CSU trial interim population fully enrolled; data expected Q4 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.61,"consensus_revenue_estimate":null,"consensus_revenue_actual":22681000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":874861795.2258824,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":50524,"accession_number":"0001193125-26-220671","cik":1671858,"company_name":"ARS Pharmaceuticals, Inc.","ticker":"SPRY","form_type":"8-K","filed_at":"2026-05-13T12:15:06+00:00","items":["5.02","9.01"],"status":"ready","headline":"ARS Pharma appoints Donn Casale as President effective June 1, 2026","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Donn Casale, 53, most recently Chief Commercial Officer at Dynavax (acquired by Sanofi), joins as President.","Casale will receive an annual base salary of $575,000 and target annual discretionary bonus of 45% of base.","Stock option grant valued at ~$6M under 2020 Equity Incentive Plan; exercise price = grant date closing price.","Option vests 25% after one year, then monthly over 36 months; subject to continued employment.","He replaces Richard Lowenthal as President; Lowenthal remains CEO."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":874861795.2258824,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107041,"accession_number":"0001193125-26-097467","cik":1671858,"company_name":"ARS Pharmaceuticals, Inc.","ticker":"SPRY","form_type":"8-K","filed_at":"2026-03-09T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"ARS Pharma reports $72.2M neffy sales in first full year; net loss $171.3M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Full-year U.S. neffy net product revenue $72.2M; total revenue $84.3M including $9.7M partner revenue.","FY 2025 net loss $171.3M ($1.74/sh); Q4 net loss $41.3M ($0.42/sh).","Cash $245.0M at Dec 31, 2025; expects to fund operations through cash-flow break-even.","Sales force to expand from 106 to 150 in Q2 2026; >22,500 HCPs prescribed neffy, 50% repeat.","Phase 2b CSU trial interim data H2 2026; Canada approval expected Q2 2026 with ALK."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":874861795.2258824,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":123381,"accession_number":"0001193125-25-273107","cik":1671858,"company_name":"ARS Pharmaceuticals, Inc.","ticker":"SPRY","form_type":"8-K","filed_at":"2025-11-10T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"ARS Pharma reports Q3 net loss $51.2M; neffy net product revenue $31.3M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 2025 total revenue $32.5M, including $31.3M neffy U.S. net product revenue; net loss $51.2M ($0.52/share).","SG&A expenses $74.8M, driven by DTC campaign; cash position $288.2M, including $100M term loan draw.","Over 18,000 HCPs have prescribed neffy (86% increase from Aug 2025); consumer awareness rose from 20% to 56%.","Japan approval for neffy in Sep 2025; U.K. launch of EUR neffy in Oct 2025; EU approval for 1 mg expected H1 2026.","Phase 2b urticaria trial enrolling; topline data anticipated mid-2026; company targets cash-flow breakeven."],"consensus_eps_estimate":-0.4814,"consensus_eps_actual":-1.32,"consensus_revenue_estimate":null,"consensus_revenue_actual":56191000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":874861795.2258824,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":140044,"accession_number":"0001193125-25-223228","cik":1671858,"company_name":"ARS Pharmaceuticals, Inc.","ticker":"SPRY","form_type":"8-K","filed_at":"2025-09-29T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"ARS Pharmaceuticals enters $250M credit facility, draws $100M upfront","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["$100M Term A Loan drawn Sep 29 2025; up to $250M total available in four tranches.","Interest: SOFR + 3% floor + 5.50% margin; can decrease 50 bps based on revenue milestones.","Proceeds fund R&D, product development, and commercialization of neffy.","Term loans mature 5 years from closing; PIK interest option available for first 2 years.","Lenders include affiliates of OMERS and RA Capital; RA Capital is largest stockholder."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":874861795.2258824,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":140043,"accession_number":"0001193125-25-190202","cik":1671858,"company_name":"ARS Pharmaceuticals, Inc.","ticker":"SPRY","form_type":"8-K","filed_at":"2025-08-28T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"ARS Pharma receives Paragraph IV notice from Lupin for generic neffy; intends to sue","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Lupin filed ANDA for generic version of neffy (epinephrine nasal spray) before expiration of 8 Orange Book-listed patents.","Notice alleges patents are invalid, unenforceable, or not infringed; ARS plans to file patent infringement suit within 45 days.","Filing suit within 45 days triggers automatic 30-month FDA approval stay; company vows to vigorously defend IP.","As of filing, no other ANDA filers known; neffy is ARS's sole marketed product."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":874861795.2258824,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":140042,"accession_number":"0000950170-25-107617","cik":1671858,"company_name":"ARS Pharmaceuticals, Inc.","ticker":"SPRY","form_type":"8-K","filed_at":"2025-08-13T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"ARS Pharma Q2 revenue $15.7M, neffy volume +180% QoQ, net loss $44.9M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue $15.7M, including $12.8M neffy U.S. net product revenue and $2.6M milestone from ALK.","Net loss of $44.9M ($0.46/sh); SG&A $54.3M driven by DTC campaign; cash $240.1M.","neffy weekly script volumes grew ~180% from Q1 end to Q2 end; 93% commercial coverage achieved.","EUR neffy approved in UK and launched in Germany; $5M milestone triggered from ALK.","Phase 2b urticaria trial initiated; topline data expected H1 2026."],"consensus_eps_estimate":-0.4794,"consensus_eps_actual":-0.8,"consensus_revenue_estimate":null,"consensus_revenue_actual":23690000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":874861795.2258824,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":157687,"accession_number":"0001193125-25-148922","cik":1671858,"company_name":"ARS Pharmaceuticals, Inc.","ticker":"SPRY","form_type":"8-K","filed_at":"2025-06-26T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"ARS Pharma stockholders elect four Class II directors, ratify Ernst & Young as auditor","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Elect directors Richard Lowenthal, Peter Kolchinsky, Brenton Saunders, Peter Thompson to 2028 term.","Lowenthal receives 64.9M votes for, 3.0M withheld; Kolchinsky 55.8M for, 12.1M withheld.","Saunders gets 56.2M for, 11.8M withheld; Thompson gets 61.8M for, 6.1M withheld.","Broker non-votes on director election: 9.6M shares for each nominee.","Auditor ratification passes with 77.3M for, 0.2M against; no broker non-votes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"market_cap_usd":874861795.2258824,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":157686,"accession_number":"0000950170-25-070899","cik":1671858,"company_name":"ARS Pharmaceuticals, Inc.","ticker":"SPRY","form_type":"8-K","filed_at":"2025-05-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"ARS Pharma Q1 neffy revenue $7.8M, net loss $33.9M; commercial progress with 5,000+ prescribers","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net product revenue of $7.8M from neffy; total revenue $8.0M; net loss $33.9M ($0.35 per share).","Cash, equivalents and investments $275.7M; company says runway adequate for over three years.","More than 5,000 HCPs prescribed neffy; co-promotion with ALK expands reach to ~20,000 HCPs including pediatricians.","57% commercial coverage secured; neffy 1mg now available for children 4+ weighing 15-30 kg.","Regulatory decisions expected mid-2025 in UK, year-end in Canada; German launch mid-2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.35,"consensus_revenue_estimate":null,"consensus_revenue_actual":7973000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":874861795.2258824,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":157685,"accession_number":"0001193125-25-110696","cik":1671858,"company_name":"ARS Pharmaceuticals, Inc.","ticker":"SPRY","form_type":"8-K","filed_at":"2025-05-02T23:59:59+00:00","items":["1.01"],"status":"ready","headline":"ARS Pharma and ALK co-promote neffy nasal spray to up to 9,000 U.S. pediatricians","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Co-promotion agreement with ALK-Abelló, Inc. for neffy (epinephrine nasal spray) targeting pediatricians and other prescribers.","ALK starts promotion activities May 2025, must meet ramp-up milestones and minimum detail requirements; non-compete on injectable epinephrine.","ARS books all U.S. sales; ALK receives base fee (first-year deferred) and performance bonuses from year 2: 30% of net sales above preset market share thresholds.","Agreement expires after 4 years; termination provisions include for convenience (with fee) and change of control (mid-seven to low eight-digit fee)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":874861795.2258824,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":176059,"accession_number":"0000950170-25-042317","cik":1671858,"company_name":"ARS Pharmaceuticals, Inc.","ticker":"SPRY","form_type":"8-K","filed_at":"2025-03-20T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"ARS Pharma Q4 net income $49.9M, neffy sales $6.7M; pediatric approval expands market","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["neffy net product revenue $7.3M for FY2024 since Sep launch; Q4 net product revenue $6.7M.","FDA approved neffy 1 mg for children 4+ and 15-30 kg on Mar 5, 2025; in pharmacies May 2025.","Cash, equivalents & short-term investments $314M; operating runway at least 3 years.","Payer coverage: >60% commercial lives under contract by end Q1 2025; >80% by early Q3.","Phase 2b trial for chronic urticaria planned Q2 2025; topline data early 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":874861795.2258824,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":176058,"accession_number":"0001193125-25-047351","cik":1671858,"company_name":"ARS Pharmaceuticals, Inc.","ticker":"SPRY","form_type":"8-K","filed_at":"2025-03-05T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"FDA approves ARS Pharma's neffy 1 mg for pediatric allergic reactions","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA approved neffy 1 mg (epinephrine nasal spray) on March 5, 2025 for children aged 4+ weighing 15-30 kg.","Approval based on trials showing PK/PD consistent with injectable epinephrine; adverse events mild/transient.","neffy 1 mg expected to be available in the U.S. by end of May 2025.","Follows prior FDA approval of neffy 2 mg (Aug 2024) for patients ≥30 kg and EU approval (Aug 2024).","Human factors studies show children as young as 10 and untrained individuals can administer effectively."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":874861795.2258824,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":176057,"accession_number":"0001193125-25-005014","cik":1671858,"company_name":"ARS Pharmaceuticals, Inc.","ticker":"SPRY","form_type":"8-K","filed_at":"2025-01-13T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"ARS Pharma reports preliminary Q4 2024 neffy revenue of $6.5M, cash $314M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Preliminary neffy net product revenue for Q4 2024 was approximately $6.5 million, total 2024 revenue $7.1 million since launch on Sept 23.","Cash, cash equivalents and short-term investments were $314.0 million as of Dec 31, 2024, sufficient for at least three years.","More than 14,500 neffy two-pack units delivered in Q4 2024; over 3,000 healthcare providers prescribed neffy to date.","Express Scripts added neffy to commercial formularies in Nov 2024; targeting over 80% commercial coverage by Q3 2025.","sNDA for neffy 1 mg (children 15-30 kg) has PDUFA date March 6, 2025; launch expected Q2 2025 if approved."],"consensus_eps_estimate":null,"consensus_eps_actual":0.08,"consensus_revenue_estimate":null,"consensus_revenue_actual":89149000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":874861795.2258824,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":192976,"accession_number":"0000950170-24-125921","cik":1671858,"company_name":"ARS Pharmaceuticals, Inc.","ticker":"SPRY","form_type":"8-K","filed_at":"2024-11-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"ARS Pharma Q3 net loss $19.1M; neffy launch progressing; ALK deal $145M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $19.1M for Q3 2024; total revenue of $2.1M including $0.6M neffy product revenue from one week of sales.","Cash, equivalents & short-term investments $204.6M at Sept 30; pro forma $349.6M after $145M upfront from ALK-Abelló deal.","FDA granted priority review for neffy 1mg sNDA; PDUFA date March 6, 2025 for children weighing 15-30 kg.","Exclusive license with ALK-Abelló for neffy in Europe, Canada, etc.; total consideration up to $465M plus double-digit royalties.","Over 5,700 HCPs reached, 1,700+ prescriptions submitted, and 1,000 allergists enrolled in neffy Experience Program since launch."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.43,"consensus_revenue_estimate":null,"consensus_revenue_actual":2568000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":874861795.2258824,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":192975,"accession_number":"0001193125-24-255185","cik":1671858,"company_name":"ARS Pharmaceuticals, Inc.","ticker":"SPRY","form_type":"8-K","filed_at":"2024-11-12T23:59:59+00:00","items":["1.01"],"status":"ready","headline":"ARS Pharma licenses neffy to ALK for $145M upfront; up to $320M milestones","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Upfront $145M from ALK; regulatory/commercial milestones up to $20M and sales milestones up to $300M.","Exclusive license for epinephrine nasal spray (neffy) outside US, Japan, China, Australia, New Zealand for all human uses.","Tiered royalties in mid-to-high teens on net sales; ARS supplies product for first 5 years under supply agreement.","ALK must use commercially reasonable efforts for regulatory approval and commercialization; ARS may terminate if ALK sells competing non-injectable epinephrine in US.","Deal covers anaphylaxis and Type I allergic reactions; parties may agree on future indications."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":874861795.2258824,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":192974,"accession_number":"0001193125-24-237191","cik":1671858,"company_name":"ARS Pharmaceuticals, Inc.","ticker":"SPRY","form_type":"8-K","filed_at":"2024-10-15T23:59:59+00:00","items":["1.01"],"status":"ready","headline":"ARS Pharma enters long-term supply agreement for neffy glass microvials through 2035","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Upfront payment of €3 million to Nuova Ompi for glass microvial supply.","Supplier must establish manufacturing force and capabilities to meet obligations.","Annual minimum purchase quantities and capped annual price adjustments specified.","Supply agreement expires December 31, 2035; termination for breach or reasonable business reasons."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":874861795.2258824,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":209345,"accession_number":"0001193125-24-223676","cik":1671858,"company_name":"ARS Pharmaceuticals, Inc.","ticker":"SPRY","form_type":"8-K","filed_at":"2024-09-23T23:59:59+00:00","items":["1.01"],"status":"ready","headline":"ARS Pharmaceuticals amends manufacturing agreement with Renaissance Lakewood for neffy nasal spray","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Second amendment to manufacturing agreement for neffy executed September 17, 2024.","Initial term extended to five years after U.S. commercial launch and five years after EU launch, with automatic two-year renewals.","Termination provisions revised for breach, insolvency, regulatory denial/withdrawal, force majeure, and trade law violations.","Agreement covers neffy (epinephrine nasal spray) for anaphylaxis treatment."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":874861795.2258824,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":209344,"accession_number":"0001193125-24-198384","cik":1671858,"company_name":"ARS Pharmaceuticals, Inc.","ticker":"SPRY","form_type":"8-K","filed_at":"2024-08-12T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"FDA approves ARS Pharma's neffy epinephrine nasal spray for allergic reactions","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA approved neffy on Aug 9, 2024 for emergency treatment of anaphylaxis in adults and children ≥30 kg.","Approval based on five registration studies showing pharmacokinetic/pharmacodynamic data within range of approved injectable epinephrine.","neffy expected to be available in US within 8 weeks; plan to file sNDA for children 15-<30 kg by end of Q3 2024.","CHMP positive opinion in EU on June 27; EMA decision expected Q3 2024; European commercial launch expected Q4 2024 via partner."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":874861795.2258824,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":209343,"accession_number":"0000950170-24-091745","cik":1671858,"company_name":"ARS Pharmaceuticals, Inc.","ticker":"SPRY","form_type":"8-K","filed_at":"2024-08-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"ARS Pharma Q2 net loss $12.5M; neffy PDUFA Oct 2; cash $218.7M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash, equivalents and short-term investments $218.7M as of June 30, 2024, providing at least three years of operating runway.","Net loss $12.5M vs $17.4M in Q2 2023; R&D $6.9M, G&A $8.9M.","neffy NDA under FDA review; draft physician labeling received; PDUFA target action date October 2, 2024.","EURneffy received CHMP positive opinion; formal EU marketing authorization expected Q3 2024.","Phase 2b outpatient study of neffy for urticaria on track to start dosing in Q4 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.24,"consensus_revenue_estimate":null,"consensus_revenue_actual":500000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":874861795.2258824,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":227333,"accession_number":"0001193125-24-172166","cik":1671858,"company_name":"ARS Pharmaceuticals, Inc.","ticker":"SPRY","form_type":"8-K","filed_at":"2024-06-28T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"ARS Pharmaceuticals updates corporate presentation; no new material financial data disclosed in filing text","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["ARS Pharmaceuticals (SPRY) filed an updated corporate presentation on June 28, 2024, under Item 7.01 FD disclosure.","The filing text does not contain specific new financial, operational, or strategic details; only a presentation title is provided.","No revenue, EPS, guidance, or other material metrics are available from the excerpted exhibit.","The 8-K is a routine update for investor meetings; no event-type triggers (earnings, M&A, leadership change) are indicated."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":874861795.2258824,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":227332,"accession_number":"0001193125-24-171204","cik":1671858,"company_name":"ARS Pharmaceuticals, Inc.","ticker":"SPRY","form_type":"8-K","filed_at":"2024-06-28T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"CHMP recommends EU marketing authorization for ARS Pharma's epinephrine nasal spray EURneffy","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["CHMP adopted positive opinion for EURneffy (2 mg epinephrine nasal spray) for emergency anaphylaxis treatment.","Indicated for adults and children ≥30 kg; EC decision expected within 67 days of June 27, 2024.","EURneffy is a needle-free alternative to injectable epinephrine, potentially expanding treatment access.","Corporate presentation updated for investor meetings; no financial guidance changes reported."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":874861795.2258824,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":227331,"accession_number":"0001193125-24-165812","cik":1671858,"company_name":"ARS Pharmaceuticals, Inc.","ticker":"SPRY","form_type":"8-K","filed_at":"2024-06-21T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"ARS Pharmaceuticals stockholders elect three Class I directors, ratify EY as auditor at 2024 annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Shareholders elected Rajeev Dadoo, Michael Kelly, and Pratik Shah as Class I directors for terms expiring at 2027 annual meeting.","Proposal to ratify Ernst & Young as independent auditor for FY 2024 passed with over 79.9M votes for, 0.03M against.","Total shares outstanding and entitled to vote were 96,894,394 as of record date April 24, 2024.","Broker non-votes were 7.6M to 7.8M on director elections, none on auditor ratification.","All proposals received significant majority votes for."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":874861795.2258824,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":227330,"accession_number":"0001193125-24-135721","cik":1671858,"company_name":"ARS Pharmaceuticals, Inc.","ticker":"SPRY","form_type":"8-K","filed_at":"2024-05-10T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"ARS Pharmaceuticals updates corporate presentation; no specific new details disclosed","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Filed an updated corporate presentation for investor meetings on May 10, 2024.","Presentation available on company website; no material financial or operational updates provided.","No earnings, guidance, or pipeline changes mentioned in the filing text or exhibit title.","Investors should review the full presentation for any potential updates not summarized here."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":874861795.2258824,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":227329,"accession_number":"0000950170-24-056934","cik":1671858,"company_name":"ARS Pharmaceuticals, Inc.","ticker":"SPRY","form_type":"8-K","filed_at":"2024-05-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"ARS Pharma reports Q1 net loss $10.3M; neffy PDUFA date Oct 2, 2024; cash $223.6M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Cash and securities $223.6M as of March 31, 2024; expected operating runway at least three years.","Net loss $10.3M for Q1 2024 compared to $15.0M in Q1 2023; R&D expenses $5.2M, G&A $8.0M.","FDA PDUFA target date for neffy NDA is October 2, 2024; CRL response submitted April 2.","European CHMP opinion on neffy MAA expected in Q2 2024; Day 180 response submitted April 30.","Exclusive license agreement with CSL Seqirus for Australia and New Zealand; up to $5M in payments."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":874861795.2258824,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":246209,"accession_number":"0000950170-24-034678","cik":1671858,"company_name":"ARS Pharmaceuticals, Inc.","ticker":"SPRY","form_type":"8-K","filed_at":"2024-03-21T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"ARS Pharma to submit CRL response in early Q2 2024; Q4 net loss $7.2M, cash $228.4M","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["CRL response for neffy (epinephrine nasal spray) to be submitted early Q2 2024; FDA action and potential launch expected H2 2024.","Phase 2 urticaria trial met primary endpoints with rapid symptom control; outpatient study planned later in 2024.","Cash, equivalents and short-term investments $228.4M as of Dec 31, 2023; runway at least three years.","Net loss $7.2M in Q4, $54.4M full year 2023; R&D costs $3.4M in Q4, G&A $6.8M.","EMA MAA decision for neffy expected mid-2024; new U.S. patent issued covering intranasal epinephrine methods."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":874861795.2258824,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":246208,"accession_number":"0001193125-24-061842","cik":1671858,"company_name":"ARS Pharmaceuticals, Inc.","ticker":"SPRY","form_type":"8-K","filed_at":"2024-03-07T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"ARS Pharma discloses $228M cash; neffy investor day presentation published","summary_kind":"llm","event_type":"other_material","confidence":"medium","bullets":["Cash and short-term investments of ~$228M as of December 31, 2023.","Updated corporate presentation for neffy (epinephrine nasal spray) shared with investors.","No additional financial results or forward guidance provided in the 8-K."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":874861795.2258824,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":263654,"accession_number":"0000950170-23-061989","cik":1671858,"company_name":"ARS Pharmaceuticals, Inc.","ticker":"SPRY","form_type":"8-K","filed_at":"2023-11-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"ARS Pharmaceuticals Q3 net loss $14.9M; neffy NDA resubmission anticipated H1 2024","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash, equivalents and short-term investments $241.9M as of Sep 30, 2023; operating runway ≥3 years.","Net loss $14.9M for Q3 2023; R&D $3.0M, G&A $15.0M.","FDA issued Complete Response Letter in Sep 2023 for neffy; repeat-dose study topline expected Q1 2024.","NDA resubmission planned H1 2024; potential U.S. launch in H2 2024 if approved.","European MAA decision expected Q2 2024; positive clinical results published in JACI."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.5,"consensus_revenue_estimate":null,"consensus_revenue_actual":30000.0,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":874861795.2258824,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":280876,"accession_number":"0001193125-23-241345","cik":1671858,"company_name":"ARS Pharmaceuticals, Inc.","ticker":"SPRY","form_type":"8-K","filed_at":"2023-09-25T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"ARS Pharma updates corporate presentation for Q4 2023 investor meetings","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Company posted updated corporate presentation on its website and furnished as Exhibit 99.1.","Presentation covers pipeline, clinical data, and commercial strategy for neffy (epinephrine nasal spray).","No financial updates or forward guidance included in the filing or presentation summary provided.","Presentation is furnished under Regulation FD; not incorporated by reference into SEC filings."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":874861795.2258824,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":280875,"accession_number":"0001193125-23-237996","cik":1671858,"company_name":"ARS Pharmaceuticals, Inc.","ticker":"SPRY","form_type":"8-K","filed_at":"2023-09-20T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"ARS Pharma receives FDA Complete Response Letter for neffy; plans appeal, resubmission H1 2024","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA CRL requests a repeat-dose PK/PD study in allergen-induced allergic rhinitis conditions for approval.","Company will file a Formal Dispute Resolution Request to appeal the CRL; advisory committee voted 16-6/17-5 in favor May 2023.","CRL also asks for nitrosamine impurity testing; company says not rate-limiting for resubmission.","Resubmission expected first half 2024 with FDA action target second half 2024.","Prior FDA alignment on the repeat-dose study as a post-marketing commitment; CRL now requires it for approval."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":874861795.2258824,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":280874,"accession_number":"0000950170-23-041294","cik":1671858,"company_name":"ARS Pharmaceuticals, Inc.","ticker":"SPRY","form_type":"8-K","filed_at":"2023-08-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"ARS Pharma reports Q2 net loss $17.4M; neffy PDUFA date Sept 19, 2023","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Cash, equivalents and short-term investments $252.2M as of June 30, 2023, funding at least three years.","R&D expense $7.3M, G&A $13.3M, net loss $17.4M for Q2 2023.","PDUFA target action date for neffy NDA (intranasal epinephrine) set for September 19, 2023.","FDA Advisory Committee voted 16:6 adults, 17:5 children for favorable benefit-risk profile.","Commercial preparations underway; hiring 115 field reps; European MAA decision expected by year end 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":874861795.2258824,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":299527,"accession_number":"0001193125-23-177543","cik":1671858,"company_name":"ARS Pharmaceuticals, Inc.","ticker":"SPRY","form_type":"8-K","filed_at":"2023-06-28T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"ARS Pharmaceuticals stockholders elect three Class III directors at 2023 annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Elected Saqib Islam, Phillip Schneider, Laura Shawver as Class III directors to serve until 2026.","Director vote results: Islam 70.4M for, 3.4M withheld; Schneider 68.7M for, 5.1M withheld; Shawver 69.7M for, 4.1M withheld.","Ratified Ernst & Young as independent auditor for FY2023 with 79.1M votes for, 5,126 against, 4,843 abstentions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":874861795.2258824,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":299526,"accession_number":"0001193125-23-146147","cik":1671858,"company_name":"ARS Pharmaceuticals, Inc.","ticker":"SPRY","form_type":"8-K","filed_at":"2023-05-16T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"ARS Pharmaceuticals releases revised corporate presentation highlighting its needle-free epinephrine device","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["ARS Pharmaceuticals released a revised corporate presentation on May 16, 2023.","Presentation highlights the company's needle-free epinephrine product for allergic reactions.","No earnings, clinical results, or regulatory milestones were disclosed in the filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":874861795.2258824,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":299525,"accession_number":"0000950170-23-021996","cik":1671858,"company_name":"ARS Pharmaceuticals, Inc.","ticker":"SPRY","form_type":"8-K","filed_at":"2023-05-15T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"ARS Pharma neffy FDA Panel Vote 'Favorable'; Q1 Net Loss $15.0M, Cash $264.5M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["FDA advisory committee voted 16:6 (adults) and 17:5 (children) that neffy benefit-risk is favorable.","PDUFA target action date anticipated mid-2023; NDA and MAA under review in US and EU.","Cash $264.5M, sufficient for at least three years including planned neffy launch.","Net loss $15.0M for Q1 2023; R&D $6.6M, G&A $12.2M.","Commercial launch prep underway with planned 125-person salesforce."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.16,"consensus_revenue_estimate":null,"consensus_revenue_actual":20000.0,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":874861795.2258824,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":299524,"accession_number":"0001193125-23-139053","cik":1671858,"company_name":"ARS Pharmaceuticals, Inc.","ticker":"SPRY","form_type":"8-K","filed_at":"2023-05-09T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"ARS Pharma faces FDA AdCom on May 11 for neffy (intranasal epinephrine); PK/PD sufficiency debated","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA AdCom to discuss whether PK/PD data for ARS-1 (intranasal epinephrine) sufficiently establish efficacy for anaphylaxis; meeting scheduled May 11, 2023.","Development program relies on PK/PD similarity to injection products rather than clinical efficacy trials; FDA questions translatability to anaphylaxis patients.","FDA notes PK/PD discrepancy: ARS-1 has lower epinephrine PK than EpiPen but higher/more sustained SBP/PR response; ARS argues this supports efficacy.","Proposed dose: 2 mg intranasal (one spray) for adults and children ≥30 kg, with optional second dose after 10 minutes if needed.","Human factors validation studies support usability; committee asked to weigh benefit-risk considering needle-free alternative to injectable epinephrine."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":874861795.2258824,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":319669,"accession_number":"0000950170-23-009485","cik":1671858,"company_name":"ARS Pharmaceuticals, Inc.","ticker":"SPRY","form_type":"8-K","filed_at":"2023-03-23T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"ARS Pharma reports FY2022 net loss $34.7M; neffy NDA under FDA review, PDUFA mid-2023","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $14.4M for Q4 2022 and $34.7M for full year 2022; cash & investments $274.4M as of Dec 31, 2022.","NDA for neffy (intranasal epinephrine) accepted by FDA; PDUFA target action date anticipated in mid-2023.","MAA for neffy also under review by EMA; company reacquired European rights.","R&D expenses $4.7M (Q4) and $18.4M (FY); G&A $10.7M (Q4) and $18.5M (FY).","Cash runway sufficient for at least three years; preparing for potential U.S. launch in 2023 if approved."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":874861795.2258824,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":319668,"accession_number":"0001193125-23-068584","cik":1671858,"company_name":"ARS Pharmaceuticals, Inc.","ticker":"SPRY","form_type":"8-K","filed_at":"2023-03-13T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"ARS Pharmaceuticals updates corporate presentation; no material new details disclosed","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Filed a Form 8-K on March 13, 2023, to furnish an updated corporate presentation.","Presentation highlights neffy as 'first no-needle, no-injection solution' for Type I allergic reactions.","No financial, clinical, or regulatory milestones were reported in the filing or the title slide of Exhibit 99.1.","Presentation is available on the company's website; content beyond the title slide is not provided."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":874861795.2258824,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":319667,"accession_number":"0001193125-23-044823","cik":1671858,"company_name":"ARS Pharmaceuticals, Inc.","ticker":"SPRY","form_type":"8-K","filed_at":"2023-02-22T23:59:59+00:00","items":["1.01","1.02"],"status":"ready","headline":"ARS Pharma terminates Recordati license for neffy in EU/UK/MEA; reacquires rights for €3M upfront plus milestones","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Terminated License and Supply Agreement with Recordati Ireland, effective immediately.","Reacquired exclusive rights to neffy (epinephrine) for EU, UK, Middle East, Africa, Eurasia.","Pays €3.0M upfront; Recordati eligible for up to €2.0M EMA milestone, €5.0M first commercial sale, up to €5.0M sales milestones.","Total potential milestone payments to Recordati up to €12.0M.","ARS regains control of development, manufacturing, regulatory, and commercialization in the territory."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":874861795.2258824,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":319666,"accession_number":"0001193125-23-036914","cik":1671858,"company_name":"ARS Pharmaceuticals, Inc.","ticker":"SPRY","form_type":"8-K","filed_at":"2023-02-14T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"ARS Pharma reports $275M cash as of Dec 31, 2022; updates corporate presentation","summary_kind":"llm","event_type":"other","confidence":"medium","bullets":["Cash and securities of approximately $275 million as of December 31, 2022.","Updated corporate presentation (Exhibit 99.1) highlights needle-free epinephrine solution for allergic reactions.","No additional financial results, guidance, or operational milestones disclosed in this filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":874861795.2258824,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":319665,"accession_number":"0001193125-23-009540","cik":1671858,"company_name":"ARS Pharmaceuticals, Inc.","ticker":"SPRY","form_type":"8-K/A","filed_at":"2023-01-17T23:59:59+00:00","items":["9.01"],"status":"ready","headline":"ARS Pharma files merger financials: 2021 revenue $5.5M, net loss $20.2M","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Audited 2021 revenue $5.5M vs $17.8M in 2020; net loss $20.2M vs $1.1M.","Cash $60.1M at Dec 31, 2021; accumulated deficit $42.3M; expects continued losses.","Product candidate ARS-1 (Neffy) for needle-free epinephrine in anaphylaxis.","Merger with Silverback closed Nov 2022; this amendment provides previously missing financials.","Pro forma combined financials filed as Exhibit 99.3; shows combined entity post-merger."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":874861795.2258824,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":337870,"accession_number":"0001193125-22-301873","cik":1671858,"company_name":"ARS Pharmaceuticals, Inc.","ticker":"SPRY","form_type":"8-K","filed_at":"2022-12-09T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"ARS Pharmaceuticals appoints Brian Dorsey as COO; salary increased to $410,000","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Brian Dorsey appointed COO effective December 6, 2022; previously SVP of Operations and Project Management since 2018.","Base salary raised from $319,800 to $410,000; eligible for annual discretionary bonus up to 40% of base salary.","Employment agreement is part-time (~35%); Dorsey may engage in other business activities, subject to non-compete in nasal drug development.","Severance: 3 months base salary and COBRA premiums if terminated without cause or resigns for good reason after 12-month cliff.","Dorsey holds 120,000-share option grant under 2018 Equity Incentive Plan, vesting monthly over 3 years."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":874861795.2258824,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":337869,"accession_number":"0001193125-22-299482","cik":1671858,"company_name":"ARS Pharmaceuticals, Inc.","ticker":"SPRY","form_type":"8-K","filed_at":"2022-12-06T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"ARS Pharmaceuticals updates corporate presentation; no material new data disclosed","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Company released an updated slide deck for investor meetings on December 6, 2022.","Presentation highlights needle-free epinephrine solution for Type I allergic reactions.","No new clinical, regulatory, or financial milestones were announced in the filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":874861795.2258824,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":337874,"accession_number":"0001193125-22-280241","cik":1671858,"company_name":"ARS Pharmaceuticals, Inc.","ticker":"SPRY","form_type":"8-K","filed_at":"2022-11-08T23:59:59+00:00","items":["2.01","1.01","5.07","3.02","5.01","5.02","5.03","8.01","9.01"],"status":"ready","headline":"Silverback Therapeutics merges with ARS Pharma; renamed ARS Pharmaceuticals, new board and focus on neffy","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Merger completed Nov 8, 2022; ARS Pharma becomes wholly owned subsidiary of re-named ARS Pharmaceuticals, Inc.","ARS Pharma equityholders own ~62% and prior Silverback equityholders ~38% on a fully diluted basis post-merger.","New board includes eight ARS Pharma designees; executives: Richard Lowenthal (CEO), Kathleen Scott (CFO), Sarina Tanimoto (CMO), Eric Karas (CCO), Justin Chakma (CBO/Secretary).","Company now focusing on neffy (intranasal epinephrine) for Type I allergic reactions and anaphylaxis.","Stock symbol changes from SBTX to SPRY, effective Nov 9, 2022, on Nasdaq."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":1.0,"calibrated_materiality_score":1.0,"market_cap_usd":874861795.2258824,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":337873,"accession_number":"0001193125-22-275336","cik":1671858,"company_name":"ARS Pharmaceuticals, Inc.","ticker":"SPRY","form_type":"8-K","filed_at":"2022-11-02T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Silverback Therapeutics announces final exchange ratio of 1.1819 for merger with ARS Pharma","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Final exchange ratio set at 1.1819 per the Merger Agreement as amended on October 25, 2022.","Merger with ARS Pharmaceuticals remains subject to stockholder approval and other closing conditions.","Shareholders are urged to read the definitive proxy statement filed on October 6, 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":874861795.2258824,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":337872,"accession_number":"0001193125-22-270962","cik":1671858,"company_name":"ARS Pharmaceuticals, Inc.","ticker":"SPRY","form_type":"8-K","filed_at":"2022-10-27T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Silverback amends merger agreement with ARS Pharma; raises net cash ceiling to $265M","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Parent Net Cash condition revised: must be between $210M and $265M, increased from $255M ceiling.","If net cash exceeds $265M, Silverback may declare a dividend for excess amount to satisfy closing condition.","Parent Valuation definition updated: adds up to $25M of cash above $240M to equity value.","Amendment signed Oct 25, 2022; merger still subject to stockholder approval and other conditions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":874861795.2258824,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":337871,"accession_number":"0001193125-22-266351","cik":1671858,"company_name":"ARS Pharmaceuticals, Inc.","ticker":"SPRY","form_type":"8-K","filed_at":"2022-10-21T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"FDA accepts ARS Pharma's NDA for neffy (epinephrine nasal spray) for allergic reactions","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA accepted NDA for neffy (epinephrine nasal spray) for emergency treatment of allergic reactions including anaphylaxis in adults and children ≥30 kg.","If approved, neffy would be first non-injectable treatment for type I allergic reactions in U.S.","PDUFA target action date anticipated in mid-2023.","NDA based on four registration studies showing pharmacokinetics comparable to injectable epinephrine; well-tolerated in over 500 individuals.","Acceptance is a milestone for Silverback's proposed merger with ARS Pharma (previously announced)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":874861795.2258824,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":355228,"accession_number":"0001193125-22-255494","cik":1671858,"company_name":"ARS Pharmaceuticals, Inc.","ticker":"SPRY","form_type":"8-K","filed_at":"2022-09-30T23:59:59+00:00","items":["1.01","1.02","9.01"],"status":"ready","headline":"Silverback Therapeutics terminates Seattle HQ lease effective Dec 31, 2022","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Terminated lease for ~19,829 sq ft at 500 Fairview Ave N, Seattle; lease expires Dec 31, 2022.","No termination fee payable to landlord; lease end contingent on new tenant lease now executed.","Tenant remains responsible for all rent through Dec 31, 2022; must surrender premises in good condition.","Silverback grants temporary license to new tenant (Approved Licensee) for premises before termination.","Company discloses it is undergoing a corporate merger; tenant entity will survive and remain liable."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":874861795.2258824,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":355227,"accession_number":"0001193125-22-237900","cik":1671858,"company_name":"ARS Pharmaceuticals, Inc.","ticker":"SPRY","form_type":"8-K","filed_at":"2022-09-02T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Silverback terminates President/CSO and CFO; appoints interim CFO ahead of merger","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Terminated Valerie Odegard (President/CSO) and Jonathan Piazza (CFO), effective Sept 2, 2022, to extend cash runway.","Odegard and Piazza entered consulting agreements at $350/hour (max 20 hrs/wk) through merger close or Nov 30, 2022.","Equity awards continue vesting during consulting period; options remain exercisable.","Russ Hawkinson appointed Interim CFO; he also serves as SVP Finance and principal accounting officer."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":874861795.2258824,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":355226,"accession_number":"0001193125-22-199246","cik":1671858,"company_name":"ARS Pharmaceuticals, Inc.","ticker":"SPRY","form_type":"8-K","filed_at":"2022-07-21T23:59:59+00:00","items":["1.01","2.05","5.02","8.01","9.01"],"status":"ready","headline":"Silverback Therapeutics to merge with ARS Pharmaceuticals; focus on needle-free epinephrine nasal spray neffy","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Silverback equity holders expected to own ~37%, ARS holders ~63% on fully-diluted basis.","Combined company expected to have ~$265M cash at close; merger expected Q4 2022; ticker to change to 'SPRY'.","Silverback to reduce workforce by ~73% by Sept 2, 2022; severance charges ~$13M cash + $2M non-cash.","ARS preparing NDA submission for neffy in Q3 2022; potential US launch in 2023.","Combined company CEO will be Rich Lowenthal (ARS); board of 10 members (7 from ARS, 3 from Silverback)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":874861795.2258824,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":373353,"accession_number":"0001193125-22-172958","cik":1671858,"company_name":"ARS Pharmaceuticals, Inc.","ticker":"SPRY","form_type":"8-K","filed_at":"2022-06-13T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Silverback Therapeutics stockholders elect directors, ratify auditor at 2022 annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Andrew Powell and Peter Thompson were elected Class II directors to serve until 2025 annual meeting.","Ernst & Young LLP was ratified as independent auditor for fiscal year ending Dec 31, 2022 with 99.8% of votes in favor.","Approximately 35.1 million shares were outstanding and entitled to vote as of April 11, 2022 record date."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":874861795.2258824,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2022-06-13T23:59:59+00:00|373353"}